🇺🇸 FDA
Pipeline program

Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension

D5989C00001 THARROS

Phase 3 small_molecule active

Quick answer

Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension for Chronic Obstructive Pulmonary Disease (COPD) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Chronic Obstructive Pulmonary Disease (COPD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials